Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time
20 juil. 2023 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
12 juin 2023 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus to Present at the Jefferies Healthcare Conference
01 juin 2023 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR
23 mai 2023 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus Reports First Quarter 2023 Financial Results
04 mai 2023 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year periodGAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP...
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
24 avr. 2023 07h30 HE
|
Lantheus Holdings, Inc.; POINT Biopharma Global Inc.
BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
20 avr. 2023 08h00 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...
Lantheus Announces Two Key Executive Promotions
17 mars 2023 08h35 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
23 févr. 2023 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectivelyGAAP net loss of...
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
16 févr. 2023 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...